Funding & Growth

Over the past year, Imago Systems’ progress has been fueled by the continued commitment of its board members and early investors, whose financial support has enabled the company to advance multiple programs in parallel. This foundation has positioned Imago to pursue its next stage of growth with confidence and momentum.

Looking ahead, Imago is broadening its investor base through new channels, including Catalyst Capital Markets, Vestech Securities, and expanded direct outreach to family offices, venture firms, and strategic investors. This diversified fundraising approach is designed not only to secure capital but also to build long-term partnerships that align with the company’s mission and growth trajectory.

The funding strategy is specifically structured to:

Sustain momentum across clinical and regulatory programs, ensuring timely advancement of both ICE Reveal and ICE Insight toward FDA clearance and international approvals.

Deliver on partner commitments across the U.S., India, Argentina/Latin America, and Egypt, strengthening Imago’s reputation as a reliable collaborator.

Accelerate commercialization pathways in high-priority geographies by investing in market readiness, distribution agreements, and customer engagement.

Enhance visibility with stakeholders and strategic partners, creating a stronger presence in the medical technology and investment communities.

In addition to equity financing, Imago is actively exploring non-dilutive capital opportunities, including grants, strategic collaborations, and industry partnerships, to complement investor commitments and extend its operational runway. Together, these initiatives form a comprehensive funding platform designed to maximize flexibility, preserve shareholder value, and support the company’s global growth ambitions.

John Boney
Investor Relations
IMAGO SYSTEMS, INC.
john@imagosystems.com
19309 Winmeade Drive| Suite 217 | Lansdowne, VA 20176
www.imagosystems.com